Cite
HARVARD Citation
Johnson, M. et al. (n.d.). 93O First results of phase I/II studies evaluating viral vector-based heterologous prime/boost immunotherapy against predicted HLA class I neoantigens demonstrate CD8 T cell responses in patients with advanced cancers. Annals of oncology. p. . [Online].